519 related articles for article (PubMed ID: 19358618)
1. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
Aronson S; Van Baelen B; Kavanagh S; Schwalen S
Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
[TBL] [Abstract][Full Text] [Related]
2. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.
Blesa R; Davidson M; Kurz A; Reichman W; van Baelen B; Schwalen S
Dement Geriatr Cogn Disord; 2003; 15(2):79-87. PubMed ID: 12566596
[TBL] [Abstract][Full Text] [Related]
3. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
4. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
5. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.
Erkinjuntti T; Kurz A; Small GW; Bullock R; Lilienfeld S; Damaraju CV;
Clin Ther; 2003 Jun; 25(6):1765-82. PubMed ID: 12860497
[TBL] [Abstract][Full Text] [Related]
6. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
[TBL] [Abstract][Full Text] [Related]
7. Galantamine for Alzheimer's disease and mild cognitive impairment.
Loy C; Schneider L
Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
[TBL] [Abstract][Full Text] [Related]
8. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.
Raskind MA; Peskind ER; Wessel T; Yuan W
Neurology; 2000 Jun; 54(12):2261-8. PubMed ID: 10881250
[TBL] [Abstract][Full Text] [Related]
9. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
[TBL] [Abstract][Full Text] [Related]
10. Effects of galantamine in patients with mild Alzheimer's disease.
Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
[TBL] [Abstract][Full Text] [Related]
11. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
[TBL] [Abstract][Full Text] [Related]
12. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.
Tariot PN; Solomon PR; Morris JC; Kershaw P; Lilienfeld S; Ding C
Neurology; 2000 Jun; 54(12):2269-76. PubMed ID: 10881251
[TBL] [Abstract][Full Text] [Related]
13. Galantamine for Alzheimer's disease.
Loy C; Schneider L
Cochrane Database Syst Rev; 2004 Oct; (4):CD001747. PubMed ID: 15495017
[TBL] [Abstract][Full Text] [Related]
14. Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.
Kavanagh S; Howe I; Brashear HR; Wang D; van Baelen B; Todd M; Schwalen S
Curr Alzheimer Res; 2011 Mar; 8(2):175-86. PubMed ID: 21222607
[TBL] [Abstract][Full Text] [Related]
15. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.
Suh GH; Yeon Jung H; Uk Lee C; Hoon Oh B; Nam Bae J; Jung HY; Ju YS; Kil Yeon B; Park J; Hong I; Choi S; Ho Lee J;
Clin Ther; 2004 Oct; 26(10):1608-18. PubMed ID: 15598477
[TBL] [Abstract][Full Text] [Related]
16. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
Small G; Erkinjuntti T; Kurz A; Lilienfeld S
CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
[TBL] [Abstract][Full Text] [Related]
17. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
[TBL] [Abstract][Full Text] [Related]
18. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
[TBL] [Abstract][Full Text] [Related]
19. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
Raskind MA; Peskind ER; Truyen L; Kershaw P; Damaraju CV
Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774
[TBL] [Abstract][Full Text] [Related]
20. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
